La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Mega Lifesciences Gestione

Gestione criteri di controllo 2/4

Mega Lifesciences' Il CEO è Vivek Dhawan, nominato in Jan1988, ha un mandato di 36.58 anni. possiede direttamente 6.62% delle azioni della società, per un valore di THB 2.24B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 26.6 anni e 11.5 anni.

Informazioni chiave

Vivek Dhawan

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	36.6yrs
Proprietà del CEO	6.6%
Durata media del management	26.6yrs
Durata media del Consiglio di amministrazione	11.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Vivek Dhawan (63 yo)

36.6yrs

Mandato

Mr. Vivek Dhawan has been the Chief Executive Officer of Mega Lifesciences Public Company Limited since 1988 and has been its Chief Coach since 2013. Mr. Dhawan started with Medicap and built Lupin Laborat...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Vivek Dhawan	CEO, Chief Coach & Executive Director	36.6yrs	Nessun dato	6.62% THB 2.2b
Thomas Abraham	CFO & Executive Director	26.6yrs	Nessun dato	0.76% THB 251.7m
Deepak Panjwani	Chief Risk & Compliance Officer	no data	Nessun dato	Nessun dato
Paramjit Sawhney	President of International	no data	Nessun dato	1.5% THB 494.0m
Girish Wadhwa	President of Myanmar	no data	Nessun dato	Nessun dato
Manoj Gurbuxani	Deputy Chief Financial Officer	4.6yrs	Nessun dato	0.000010% THB 3.3k
Duangnapa Tongsiri	President of Mega We Care Thailand	no data	Nessun dato	1.48% THB 486.3m
Sujintana Boonworapat	Corporate Secretary	no data	Nessun dato	0.021% THB 6.8m

26.6yrs

Durata media

57.5yo

Età media

Gestione esperta: Il team dirigenziale di MEGA è esperto e expertise (durata media dell'incarico 26.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Vivek Dhawan	CEO, Chief Coach & Executive Director	11.6yrs	Nessun dato	6.62% THB 2.2b
Thomas Abraham	CFO & Executive Director	26.6yrs	Nessun dato	0.76% THB 251.7m
Yim Chi	Independent Vice Chairma	11.5yrs	฿1.58m	Nessun dato
Kirit Chimanlal Shah	Non-Executive Director	11.5yrs	฿661.50k	50.13% THB 16.5b
Shiraz Poonevala	Non-Executive Director	11.5yrs	฿661.50k	Nessun dato
Ishaan Shah	Non-Executive Director	11.5yrs	฿661.50k	Nessun dato
Mechai Viravaidya	Independent Chairman	11.5yrs	฿2.21m	Nessun dato
Sameera Shah	Non-Executive Director	11.5yrs	฿661.50k	Nessun dato
Thor Santhisiri	Independent Director	11.5yrs	฿1.15m	0.013% THB 4.2m
Vijay Karwal	Independent Director	3.3yrs	฿1.15m	Nessun dato
Nithinart Sinthudeacha	Independent Director	1.6yrs	฿1.15m	Nessun dato

11.5yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di MEGA è composto da personale esperto e esperto (durata media dell'incarico 11.5 anni).

Mega Lifesciences Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Less than half of directors are independent

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Recent updates

First half dividend of ฿0.80 announced

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Upcoming dividend of ฿0.80 per share

Final dividend reduced to ฿0.80

Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Now 20% undervalued

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued

Now 21% undervalued

Upcoming dividend of ฿0.80 per share at 3.8% yield

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2023to June 30, 2023, Payable on September 8, 2023

Now 20% undervalued after recent price drop

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Now 25% undervalued after recent price drop

First quarter 2023 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ฿0.85 per share at 3.5% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Upcoming dividend of ฿0.75 per share

Second quarter 2022 earnings: Revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2022 to June 30, 2022, Payable on September 9, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Upcoming dividend of ฿0.86 per share

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited Proposes Dividend for Year Ended December 31, 2021, Payable on April 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ฿0.70 (vs ฿0.39 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of ฿0.52 per share

Second quarter 2021 earnings released: EPS ฿0.58 (vs ฿0.35 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.38 (vs ฿0.37 in 1Q 2020)

New 90-day low: ฿35.50

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ฿1.60 (vs ฿1.31 in FY 2019)

New 90-day high: ฿40.50

New 90-day high: ฿39.00

Third quarter 2020 earnings released: EPS ฿0.39

Revenue and earnings beat expectations

New 90-day low: ฿32.00

New 90-day low: ฿33.00

Mega Lifesciences Public Company Limited (SET:MEGA) completed the acquisition of 83.33% stake in PT Futamed Pharmaceuticals from PT Ersons and others for approximately IDR 180 billion.

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media